MTOR inhibition enhances NVP-AUY922-induced autophagymediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors

Yuan Shuo Hsueh, Hui Hua Chang, Nai Jung Chiang, Chueh Chuan Yen, Chien Feng Li, Li Tzong Chen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Our previous study demonstrated NVP-AUY922, a HSP90AA1 inhibitor, could enhance mutant KIT degradation in gastrointestinal stromal tumor (GIST) cells through both proteasome- and autophagy-mediated pathways. Herein, we showed rapamycin, a MTOR inhibitor and autophagy inducer, could reduce total and phospho-KIT expression levels and enhance apoptosis in imatinib-resistant GIST cells. The involvement of autophagy in rapamycin-induced KIT downregulation was further confirmed by co-localization of KIT and autophagosome, and partial recovery of KIT expression level by either siRNA-mediated BECN1 and ATG5 silencing or autophagy inhibitors after rapamycin. Rapamycin and NVP-AUY922 synergistically inhibited GIST cells growth in vitro. The combination of low-dose NVP-AUY922 with rapamycin had comparable effects on reducing KIT expression, increasing MAP1LC3B puncta and tumor necrosis, and inhibiting tumor growth as high-dose NVP-AUY922 did in GIST430 xenograft model. Our results suggest the addition of a MTOR inhibitor may reduce NVP-AUY922 dose requirement and potentially improve its therapeutic index in mutant KIT-expressing GISTs.

Original languageEnglish
Pages (from-to)11711-11724
Number of pages14
JournalOncotarget
Volume5
Issue number22
Publication statusPublished - 2014 Jan 1

Fingerprint

Gastrointestinal Stromal Tumors
Sirolimus
Autophagy
Stromal Cells
Proteasome Endopeptidase Complex
Growth
Heterografts
Small Interfering RNA
Neoplasms
Necrosis
Down-Regulation
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
Imatinib Mesylate
Apoptosis

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{01c984da92d343cd8470b678f993b9e1,
title = "MTOR inhibition enhances NVP-AUY922-induced autophagymediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors",
abstract = "Our previous study demonstrated NVP-AUY922, a HSP90AA1 inhibitor, could enhance mutant KIT degradation in gastrointestinal stromal tumor (GIST) cells through both proteasome- and autophagy-mediated pathways. Herein, we showed rapamycin, a MTOR inhibitor and autophagy inducer, could reduce total and phospho-KIT expression levels and enhance apoptosis in imatinib-resistant GIST cells. The involvement of autophagy in rapamycin-induced KIT downregulation was further confirmed by co-localization of KIT and autophagosome, and partial recovery of KIT expression level by either siRNA-mediated BECN1 and ATG5 silencing or autophagy inhibitors after rapamycin. Rapamycin and NVP-AUY922 synergistically inhibited GIST cells growth in vitro. The combination of low-dose NVP-AUY922 with rapamycin had comparable effects on reducing KIT expression, increasing MAP1LC3B puncta and tumor necrosis, and inhibiting tumor growth as high-dose NVP-AUY922 did in GIST430 xenograft model. Our results suggest the addition of a MTOR inhibitor may reduce NVP-AUY922 dose requirement and potentially improve its therapeutic index in mutant KIT-expressing GISTs.",
author = "Hsueh, {Yuan Shuo} and Chang, {Hui Hua} and Chiang, {Nai Jung} and Yen, {Chueh Chuan} and Li, {Chien Feng} and Chen, {Li Tzong}",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "5",
pages = "11711--11724",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "22",

}

MTOR inhibition enhances NVP-AUY922-induced autophagymediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors. / Hsueh, Yuan Shuo; Chang, Hui Hua; Chiang, Nai Jung; Yen, Chueh Chuan; Li, Chien Feng; Chen, Li Tzong.

In: Oncotarget, Vol. 5, No. 22, 01.01.2014, p. 11711-11724.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MTOR inhibition enhances NVP-AUY922-induced autophagymediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors

AU - Hsueh, Yuan Shuo

AU - Chang, Hui Hua

AU - Chiang, Nai Jung

AU - Yen, Chueh Chuan

AU - Li, Chien Feng

AU - Chen, Li Tzong

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Our previous study demonstrated NVP-AUY922, a HSP90AA1 inhibitor, could enhance mutant KIT degradation in gastrointestinal stromal tumor (GIST) cells through both proteasome- and autophagy-mediated pathways. Herein, we showed rapamycin, a MTOR inhibitor and autophagy inducer, could reduce total and phospho-KIT expression levels and enhance apoptosis in imatinib-resistant GIST cells. The involvement of autophagy in rapamycin-induced KIT downregulation was further confirmed by co-localization of KIT and autophagosome, and partial recovery of KIT expression level by either siRNA-mediated BECN1 and ATG5 silencing or autophagy inhibitors after rapamycin. Rapamycin and NVP-AUY922 synergistically inhibited GIST cells growth in vitro. The combination of low-dose NVP-AUY922 with rapamycin had comparable effects on reducing KIT expression, increasing MAP1LC3B puncta and tumor necrosis, and inhibiting tumor growth as high-dose NVP-AUY922 did in GIST430 xenograft model. Our results suggest the addition of a MTOR inhibitor may reduce NVP-AUY922 dose requirement and potentially improve its therapeutic index in mutant KIT-expressing GISTs.

AB - Our previous study demonstrated NVP-AUY922, a HSP90AA1 inhibitor, could enhance mutant KIT degradation in gastrointestinal stromal tumor (GIST) cells through both proteasome- and autophagy-mediated pathways. Herein, we showed rapamycin, a MTOR inhibitor and autophagy inducer, could reduce total and phospho-KIT expression levels and enhance apoptosis in imatinib-resistant GIST cells. The involvement of autophagy in rapamycin-induced KIT downregulation was further confirmed by co-localization of KIT and autophagosome, and partial recovery of KIT expression level by either siRNA-mediated BECN1 and ATG5 silencing or autophagy inhibitors after rapamycin. Rapamycin and NVP-AUY922 synergistically inhibited GIST cells growth in vitro. The combination of low-dose NVP-AUY922 with rapamycin had comparable effects on reducing KIT expression, increasing MAP1LC3B puncta and tumor necrosis, and inhibiting tumor growth as high-dose NVP-AUY922 did in GIST430 xenograft model. Our results suggest the addition of a MTOR inhibitor may reduce NVP-AUY922 dose requirement and potentially improve its therapeutic index in mutant KIT-expressing GISTs.

UR - http://www.scopus.com/inward/record.url?scp=84964314384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964314384&partnerID=8YFLogxK

M3 - Article

C2 - 25375091

AN - SCOPUS:84964314384

VL - 5

SP - 11711

EP - 11724

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 22

ER -